Screener
aTyr Pharma ATYR Proceeds From Issuance Of Common Stock Through At Market Offering Net Of Offering Costs
Proceeds From Issuance Of Common Stock Through At Market Offering Net Of Offering Costs at other companies
Other financials
Where this comes from
Reported directly by aTyr Pharma in its filing.
Tagged under the XBRL concept atyr:ProceedsFromIssuanceOfCommonStockThroughAtMarketOfferingNetOfOfferingCosts.
The source filing: aTyr Pharma’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001339970-26-000053
FAQ
- What is aTyr Pharma's proceeds from issuance of common stock through at market offering net of offering costs?
- aTyr Pharma (ATYR) reported proceeds from issuance of common stock through at market offering net of offering costs of $0 in Q2 2026.
- How has aTyr Pharma's proceeds from issuance of common stock through at market offering net of offering costs changed year-over-year?
- aTyr Pharma's proceeds from issuance of common stock through at market offering net of offering costs decreased by 100.0% year-over-year, from $17.93M to $0.
- What is the long-term trend for aTyr Pharma's proceeds from issuance of common stock through at market offering net of offering costs?
- Over 2 years (2022 to 2025), aTyr Pharma's proceeds from issuance of common stock through at market offering net of offering costs has grown at a 248.5% compound annual growth rate (CAGR), from $5.47M to $66.44M.
- What does proceeds from issuance of common stock through at market offering net of offering costs mean?
- Proceeds From Issuance Of Common Stock Through At Market Offering Net Of Offering Costs as reported by aTyr Pharma, Inc. Common Stock.
Ask your AI about aTyr Pharma's proceeds from issuance of common stock through at market offering net of offering costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude